Evidence map›Paper›PMID 42749721›Full record

ArticleSignal transduction and targeted therapy2026

SCF

Zesen Shang, Yue Zhang, Yang Liu, Xinyi Yuan, Jichuang Wang, Dongwei Fan, Da Zou, Dazhao Tie, Fei Pei, Hongshan Zhao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zesen Shang *Department of Orthopedics, Peking University Third Hospital, Beijing, China.
Yue Zhang *Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Yang LiuDepartment of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Center for Stomatology, Beijing, China.
Xinyi YuanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, Peking University Health Science Center, Beijing, China.
Jichuang WangMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, China.
Dongwei FanDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Da ZouDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Dazhao TieDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Fei PeiDepartment of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University Third Hospital, Beijing, China.
Hongshan ZhaoDepartment of Medical Genetics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Shuguo ZhengDepartment of Preventive Dentistry, Peking University School and Hospital of Stomatology, National Center for Stomatology, Beijing, China.
Xinjing TangState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Weishi LiDepartment of Orthopedics, Peking University Third Hospital, Beijing, China. puh3liweishi@163.com.
Lin HeDepartment of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. linhe@bjmu.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82271892 and 32470822Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) 7232087
6 · The paper itself

Abstract

RUNX2 (Runt-related transcription factor 2) is a master regulator of osteogenesis, and its genetic mutations are associated with ~65% cases of cleidocranial dysplasia (CCD), an autosomal dominant abnormal bone development disorder in humans with defective intramembranous bone formation. However, how these mutations affect bone formation remains to be investigated. Here, we report that RUNX2 interacts with the F-box protein JFK and is destabilized by the SKP1-CUL1-JFK E3 ubiquitin ligase complex (SCF

Indexed as

Cell DifferentiationCleidocranial DysplasiaCore Binding Factor Alpha 1 SubunitF-Box ProteinsOsteoblastsOsteogenesisUbiquitin-Protein LigasesAnimalsHumansMiceStem Cell FactorCore Binding Factor Alpha 1 SubunitF-Box ProteinsKITLG protein, humanRUNX2 protein, humanRunx2 protein, mouseStem Cell FactorUbiquitin-Protein Ligases

Identifiers

PMID42749721
PMCPMC13582849

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.